fda warning letters compounding semaglutide september 2025 A company called Nomida has received an letter for offering for sale injectable weight-loss treatments. None of their offerings are FDA- approved. Nomida is allegedly selling unapproved and Tirzepatide "kits" August 11, 2025: The FDA
Description
Knudsen, J
POMC neurons expressing leptin receptors coordinate metabolic responses to fasting via suppression of leptin levels
Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes
Semaglutide and tirzepatide are not yet PBS listed for obesity, so retatrutide would face the same pathway and timeline challenges
Now could be the time
Vce info
